ERBB2 and familial hypercholesterolemia: No impact on CEs incidence was demonstrated for age ≥65 years (p = 0.064), hypercholesterolemia (p = 0.629), hypertension (p = 0.402), radiotherapy (p = 0.709), left side radiotherapy (p = 0.509) and dual HER2 blockade (p = 0.139) (Table S5).